Zobrazeno 1 - 10
of 157 061
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Publikováno v:
Eur J Cancer Prev
BACKGROUND Models estimating risk for advanced proximal colorectal neoplasia (APN) may be used to select colorectal cancer (CRC) screening test, either prior to knowing distal colorectal findings or afterward. Current models have only fair discrimina
Autor:
Ahmad Almatroudi, Ramesh C. Gupta, Shamama Javed, Ambreen Shoaib, Mohd Saeed, Raghuram Kandimalla, Farrukh Aqil
Publikováno v:
Seminars in Cancer Biology. 86:652-665
Cancer is one of the leading global causes of death in both men and women. Colorectal cancer (CRC) alone accounts for ∼10 % of total new global cases and poses an over 4% lifetime risk of developing cancer. Recent advancements in the field of biote
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 37:517-526
Background: Colorectal peritoneal carcinomatosis (CRPC) is a primary cause of death in colorectal cancer (CRC) patients. In the past, computed tomography (CT) has been the primary method used to ev...
Publikováno v:
Cancer Research and Treatment. 54:680-689
PurposeThe current study aimed to identify the overall characteristics of cancer-related emergency department (ED) visits by adult in Korea, including analyses of factors associated with ED stay time and outcomes nationwide. Materials and MethodsWe c
Autor:
Tae Ho Kim, Do-Kyung Kim, So-Young Lee, Soonchul Lee, Bosung Jung, Segi Kim, Dong-Eun Shin, Ji-Su Oh, Siyeong Yoon, Minsup Kim, Sang Cheol Lee
Publikováno v:
Cancer Research and Treatment. 54:937-949
PurposeMelanoma incidence is rising worldwide along with the associated personal and socioeconomic health expenditures. We investigated the incidence and survival-rate patterns of melanoma in South Korea using nationwide data. Materials and MethodsTh
Autor:
Zean Li, Xu Chen, Hui Li, Qianghua Zhou, Wenli Cai, Zhongqiu Xie, Shirong Peng, Kaiwen Li, Hai Huang, Jin Yang, Fujun Qin, Qiong Wang, Kai Yao
Publikováno v:
Cancer Biology & Medicine. 19:1193-1210
Objective To explore the genetic changes in the progression of castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) and the reason why these cancers resist existing therapies. Methods We employed our CRPC cell line mi
Autor:
Manuel Lisardo Sánchez, Rafael Coveñas
Publikováno v:
Current Medicinal Chemistry. 29:3231-3260
Background: The scientific interest regarding the involvement of peptides in cancer has increased in the last few years. In tumor cells, the overexpression of peptides and their receptors is known, and new therapeutic targets for the treatment of can